

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <https://www.tga.gov.au/reporting-problems>.

AUSTRALIAN PRODUCT INFORMATION

ZEPOSIA (ozanimod) Capsules

1. NAME OF THE MEDICINE

Australian Approved Name: ozanimod

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 230 microgram capsule contains 230 micrograms ozanimod (equivalent to 250 micrograms ozanimod hydrochloride).

Each 460 microgram capsule contains 460 micrograms ozanimod (equivalent to 500 micrograms ozanimod hydrochloride).

Each 920 microgram capsule contains 920 micrograms ozanimod (equivalent to 1.00 mg ozanimod hydrochloride).

For the full list of excipients, see Section 6.1 (List of excipients).

Description

Ozanimod hydrochloride is a white to off-white solid with a melting point of ~240°C. Ozanimod hydrochloride is poorly hygroscopic. The solubility of ozanimod hydrochloride in ethanol and methanol is 1.43 and 2.41 mg/mL and in a pH 5.1 aqueous medium is 3.51 mg/mL. The pKa for ozanimod hydrochloride is 7.90 and the partition coefficient (logP) is 3.28.

Ozanimod hydrochloride exists as the (S) configuration with an enantiomeric purity of not less than 99.0%.

3. PHARMACEUTICAL FORM

Capsule.

ZEPOSIA 230 microgram capsules:

Light grey opaque capsule, size 4, imprinted in black ink with “OZA” on the cap and “0.23 mg” on the body.

ZEPOSIA 460 microgram capsules:

Light grey / orange opaque capsule, size 4, imprinted in black ink with “OZA” on the cap and “0.46 mg” on the body.

ZEPOSIA 920 microgram capsules:

Orange opaque capsule, size 4, imprinted with “OZA” on the cap and “0.92 mg” on the body.

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Multiple Sclerosis

ZEPOSIA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis.

Ulcerative Colitis

ZEPOSIA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.

4.2. DOSE AND METHOD OF ADMINISTRATION

Treatment should be initiated under the supervision of a physician experienced in the management of multiple sclerosis (MS) or ulcerative colitis (UC).

4.2.1. Dosage

The recommended dose of ZEPOSIA for adults is 920 microgram once daily taken orally.

ZEPOSIA capsules should be swallowed whole and can be administered with or without food.

If a dose of ZEPOSIA is missed, the next scheduled dose should be taken the following day.

The initial dose escalation regimen of ZEPOSIA from Day 1 to Day 7 is shown below in Table 1. Following the 7-day dose escalation, the once daily dosage is 920 microgram taken orally starting on Day 8. Initiation of ZEPOSIA without dose escalation may result in greater reductions in heart rate (see *Section 4.4*).

Prior to Initiation of Therapy

- Obtain an electrocardiogram (ECG) to determine whether pre-existing cardiac conduction abnormalities are present (see *Section 4.4*).
- Obtain recent (i.e., within 6 months) liver function tests (see *Section 4.4*).
- Obtain a recent (i.e., within 6 months or after discontinuation of prior MS or UC therapy) complete blood count (CBC, including lymphocyte count) (see *Section 4.4*).
- Arrange an ophthalmological assessment in patients with risk factors for macular oedema, such as diabetes mellitus, history of uveitis or history of retinal disease (see *Section 4.4*).

Current or Prior Medications

- If patients are taking anti-neoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with ZEPOSIA (see *Section 4.4*).
- Determine if patients are taking drugs that could slow heart rate or atrioventricular conduction (see *Section 4.5*).

Vaccinations

Test patients for antibodies to varicella zoster virus (VZV) before initiating ZEPOSIA (see *Section 4.4*). VZV vaccination of antibody-negative patients is recommended at least 1 month prior to commencing treatment with ZEPOSIA.

If live attenuated immunisations are required, administer at least 1 month prior to initiation of ZEPOSIA (see *Section 4.4*).

4.2.2. Method of administration

Table 1: Dose Escalation Regimen

Days 1-4	230 microgram once daily
Days 5-7	460 microgram once daily
Days 8 and thereafter	920 microgram once daily

Re-initiation of therapy following treatment interruption

- If a dose of ZEPOSIA is missed during the first 2 weeks of treatment, reinitiate treatment using the dose escalation regimen.
- If a dose of ZEPOSIA is missed after the first 2 weeks of treatment, continue with the treatment as planned.
- If more than 7 consecutive days are missed between Day 15 and Day 28 of treatment, or more than 14 consecutive days after Day 28 of treatment, reinitiate treatment using the dose escalation regimen.

If the treatment interruption is of shorter duration than the above, the treatment should be continued with the next dose as planned.

Special populations

Elderly

No dose adjustment is needed in patients over 65 years of age. Caution should be used in patients over 65 years of age, given the potential for an increased risk of serious adverse reactions (infections) in this population.

Hepatic impairment

ZEPOSIA may be used with caution in patients with mild or moderate chronic hepatic impairment (Child-Pugh class A or B). Closer monitoring, which may include testing of liver function and lymphocytes count, is recommended. Steady state may take several months to reach (*see Section 5.2.6*). In patients with mild or moderate chronic hepatic impairment, the recommended dose is to complete the 7-day dose escalation regimen, and then take 920 microgram once every other day (*see Section 5.2.6*).

The pharmacokinetics of ZEPOSIA was not evaluated in subjects with severe hepatic impairment. Use in patients with severe hepatic impairment is not recommended (Child-Pugh class C).

Renal impairment

No dosage adjustment is necessary for patients with renal impairment.

Paediatric population

The safety and effectiveness of ZEPOSIA in patients below the age of 18 years have not been established.

4.3. CONTRAINDICATIONS

- Hypersensitivity to ozanimod or any of the excipients (*see Section 6.1*)
- Treatment should not be initiated in patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalisation or Class III/IV heart failure
- Treatment should not be initiated in patients who have a history or presence of second-degree atrioventricular (AV) block Type II or third-degree AV block or sick sinus syndrome unless the patient has a functioning pacemaker

- Treatment should not be initiated in patients with severe untreated sleep apnoea.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

4.4.1. Bradycardia - Reduction in heart rate

Initiation of ZEPOSIA may result in transient reductions in heart rate (HR) (*see Section 4.8*). After the initial dose of ZEPOSIA 230 microgram, the greatest mean reduction from baseline in HR was 1.2 beats per minute (bpm) in active-controlled MS clinical trials and 0.7 bpm in controlled UC clinical trials at Hour 5 on Day 1, returning to near baseline at Hour 6. HR below 40 bpm were not observed. Initiation of ZEPOSIA without dose escalation may result in greater reductions in HR (*see Section 4.2*).

If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought for those individuals:

- With significant QT prolongation (QTcF > 450 msec in males, > 470 msec in females)
- With arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic drugs

4.4.2. Liver Injury

Clinically significant liver injury has occurred in patients treated with ZEPOSIA in the post-marketing setting (*see Section 4.8*). Signs of liver injury, including elevated serum hepatic enzymes and elevated total bilirubin, have occurred as early as ten days after the first dose. Severe liver injury may result in the need for a liver transplant.

Obtain liver function tests if not recently available (i.e., within 6 months), before initiation of ZEPOSIA (*see Section 4.2.1*).

Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine, should have liver function tests checked and ZEPOSIA should be discontinued if significant liver injury is confirmed.

Resumption of therapy will be dependent on whether another cause of liver enzyme elevation is determined and on the benefits to patient of resuming therapy versus the risks of recurrence of liver dysfunction.

Patients with pre-existing liver disease may be at increased risk of developing elevated hepatic enzymes when taking ZEPOSIA.

4.4.3. Return of MS disease activity (rebound) after ZEPOSIA discontinuation

In MS, severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of another sphingosine 1-phosphate (S1P) receptor modulator. The possibility of severe exacerbation of disease after stopping ZEPOSIA treatment should be considered. Patients should be observed for relevant signs of possible severe exacerbation or return of high disease activity upon ZEPOSIA discontinuation and appropriate treatment should be instituted as required.

4.4.4. Infections

Risk of Infections

ZEPOSIA causes a mean reduction in peripheral blood lymphocyte count to approximately 45% of baseline values because of reversible retention of lymphocytes in lymphoid tissues. ZEPOSIA may therefore increase the susceptibility to infections.

Obtain a recent (i.e., within 6 months or after discontinuation of prior MS or UC therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA (*see Section 4.2.1*).

Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. After discontinuing ZEPOSIA 920 microgram, the median time to recovery of peripheral blood lymphocytes to the normal range was 30 days, with approximately 90% of patients recovering within 3 months.

Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection.

Because the elimination of ZEPOSIA after discontinuation may take up to 3 months, continue monitoring for infections throughout this period.

Prior and Concomitant Treatment with Antineoplastic, Non-corticosteroid Immunosuppressive, or Immune-modulating Therapies

In the MS and UC clinical trials, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS and UC. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of immunosuppression.

In UC clinical trials, concomitant use of corticosteroids was allowed and did not appear to influence the safety or efficacy of ZEPOSIA.

When switching to ZEPOSIA from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects (*see Section 4.5.1*).

ZEPOSIA can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.

Progressive multifocal leukoencephalopathy (PML)

PML is an opportunistic viral infection of the brain caused by the John Cunningham Virus (JCV) that typically occurs in patients who are immunocompromised and may lead to death or severe disability.

PML has been reported in patients treated with S1P receptor modulators, including ZEPOSIA, and other MS and UC therapies.

Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

Physicians should be vigilant for clinical symptoms or MRI findings that may be suggestive of PML. MRI findings may be apparent before clinical signs or symptoms. If PML is suspected, treatment with ZEPOSIA should be suspended until PML has been excluded. If confirmed, treatment with ZEPOSIA should be discontinued.

Herpes Viral Infection

Cases of localised herpes virus infection (e.g., herpes zoster and herpes simplex) were seen in clinical trials of ZEPOSIA (*see Section 4.8*).

Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against VZV, should be tested for antibodies to VZV before initiating ZEPOSIA (see Vaccinations below).

Cryptococcal Infection

Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with S1P receptor modulators. Physicians should be vigilant for clinical symptoms or signs of CM. Patients with symptoms or signs consistent with a cryptococcal infection should undergo prompt diagnostic evaluation and treatment. ZEPOSIA treatment should be suspended until a cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.

Vaccinations

Patients without a healthcare professional-confirmed history of chickenpox or without documentation of a full course of vaccination against VZV should be tested for antibodies to VZV before initiating ZEPOSIA. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIA.

No clinical data are available on the efficacy and safety of vaccinations in patients taking ZEPOSIA. Avoid the use of live attenuated vaccines during and for 3 months after treatment with ZEPOSIA.

If live *attenuated* vaccine immunisations are required, administer at least 1 month prior to initiation of ZEPOSIA. VZV vaccination of patients without documented immunity to VZV is recommended at least 1 month prior to initiating treatment with ZEPOSIA.

4.4.5. Macular Oedema

Patients observed to have macular oedema with ZEPOSIA had pre-existing risk factors (*see Section 4.8*). Patients with risk factors for macular oedema, such as a history of uveitis, diabetes mellitus or history of retinal disease, should have an ophthalmologic evaluation prior to treatment with ZEPOSIA and have follow up evaluations while receiving therapy.

Patients who present with visual symptoms of macular oedema should be evaluated and, if confirmed, treatment with ZEPOSIA should be discontinued.

4.4.6. Posterior Reversible Encephalopathy Syndrome (PRES)

PRES is a syndrome characterised by sudden onset of severe headache, confusion, seizures and visual loss. Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral haemorrhage.

In MS controlled clinical trials with ZEPOSIA, one case of PRES was reported in a patient with Guillain-Barré syndrome.

If PRES is suspected, treatment with ZEPOSIA should be discontinued.

4.4.7. Increased Blood Pressure

Hypertension was more frequently reported in patients treated with ZEPOSIA than in patients treated with IFN beta-1a IM (*see Section 4.8*) and in patients receiving concomitant ZEPOSIA and SSRIs or SNRIs.

Blood pressure should be regularly monitored during treatment with ZEPOSIA.

4.4.8. Fetal Risk

There are no adequate and well-controlled studies in pregnant women. In animals, findings at similar exposure levels included embryo-fetal death, abnormal/delayed ossification, and abnormalities of the viscera and large blood vessels.

Before initiation of treatment, women of childbearing potential must be informed of this risk to the fetus, should have a negative pregnancy test and should use effective contraception during treatment and for 3 months after stopping ZEPOSIA (*see Section 4.6.2*).

4.4.9. Malignancies

Given the immunomodulatory/immunosuppressive properties of ozanimod a potential risk for increased malignancy cannot be ruled out.

Cutaneous neoplasms

An increased risk of cutaneous malignancies has been reported with S1P receptor modulators.

Half of the neoplasms reported with ozanimod in active controlled MS clinical trials consisted of skin malignancies, with basal cell carcinoma presenting as the most common skin neoplasm and reported with a similar incidence in the combined ozanimod (0.2%, 3 patients) and IFN beta-1a (0.1 %, 1 patient) group.

In patients treated with ozanimod in controlled UC clinical trials, one patient (0.2%) had squamous cell carcinoma of the skin in the induction period, and one patient (0.4%) had basal cell carcinoma in the maintenance period. There were no cases in patients who received placebo.

Since there is a potential risk of malignant skin growths, patients treated with ZEPOSIA should be cautioned against exposure to sunlight without protection. These patients should not receive concomitant phototherapy with UV-B-radiation or PUVA-photochemotherapy.

4.4.10. Effects on Laboratory Tests

No data available.

4.5. INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Ozanimod is extensively metabolised in humans to form a number of circulating active metabolites, including two major active metabolites, CC112273 and CC1084037 and several minor active metabolites including RP101988 and RP101075.

4.5.1. Effects of other drugs on ozanimod

Caution should be applied when switching patients from long-acting therapies with immune effects (*see Section 4.4.3*)

Inhibitors of Breast Cancer Resistance Protein (BCRP)

Co-administration of ozanimod with ciclosporin (BCRP inhibitor) had no effect on the exposure of ozanimod or the major active metabolites CC112273 and CC1084037.

Strong Inhibitors of CYP2C8

The co-administration of gemfibrozil (a strong inhibitor of CYP2C8) 600 mg twice daily at steady state and a single dose of ozanimod 460 microgram increased exposure (AUC) of the major active metabolites CC112273 and CC1084037 by approximately 47% and 69%, respectively. Caution should be exercised for concomitant use of ozanimod with strong CYP2C8 inhibitors (e.g. gemfibrozil, clopidogrel).

Strong CYP3A and P-gp Inhibitors

Co-administration of itraconazole (a strong inhibitor of CYP3A and P-gp) 200 mg once daily at steady state and a single dose of ZEPOSIA 920 microgram resulted in no clinically meaningful changes in exposure of ozanimod, CC112273 and CC1084037.

Strong CYP3A/P-gp and Moderate CYP2C8 Inducers

Co-administration of rifampicin (a strong inducer of CYP3A and P-gp, and a moderate inducer of CYP2C8) 600 mg once daily at steady state and a single dose of ZEPOSIA 920 microgram resulted in no clinically meaningful changes in exposure (AUC) of ozanimod and reduced exposure (AUC) for CC112273 and CC1084037 by approximately 60% and 55%, respectively. The effect of rifampicin on CC112273 and CC1084037 was due to CYP2C8 induction. The co-administration of CYP2C8 inducers (i.e., rifampicin) with ZEPOSIA is not recommended.

Monoamine Oxidase (MAO) Inhibitors

Co-administration with MAO-B inhibitors may decrease exposure of CC112273 and consequently CC1084037. The potential for clinical interaction with MAO inhibitors has not been studied. Co-administration of MAO inhibitors (e.g., selegiline, phenelzine) with ZEPOSIA is not recommended.

Prednisone and Prednisolone

Population pharmacokinetic analyses showed that concomitant administration of prednisone or prednisolone in patients with UC did not alter the steady state exposure (AUC) of CC112273.

4.5.2. Effect of ozanimod on other drugs

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta-blockers or calcium channel blockers)

In healthy subjects, initiating ozanimod 230 microgram with steady-state propranolol long acting 80 mg once daily or diltiazem extended release 240 mg once daily did not result in any additional clinically meaningful changes in HR and PR interval compared to either propranolol or diltiazem alone.

The effect of co-administration of the maintenance dosage of ZEPOSIA, propranolol, or diltiazem, or administration with both a beta-blocker and a calcium channel blocker taken together has not been studied.

Adrenergic Agents

A placebo-controlled crossover study was conducted to assess the potential of ZEPOSIA to enhance pressor responses to pseudoephedrine in healthy subjects. Co-administration of ZEPOSIA with pseudoephedrine did not potentiate the pseudoephedrine-induced blood pressure response. ZEPOSIA increased the pseudoephedrine-induced heart rate response by approximately 3 bpm.

Oral contraceptives

Co-administration of ozanimod 920 microgram once daily and a single dose of oral contraceptive containing ethinyl estradiol (EE) 35 microgram and norethindrone (NE) 1 mg resulted in no change in EE or NE exposure. Dosing duration of ozanimod was not long enough to attain steady state for the major active metabolites; however, CC112273 and CC1084037 have no in vitro effect on CYP enzymes and therefore are not expected to have any effect on EE and NE exposure.

MAO Activity

CC112273 and CC1084037 inhibited MAO-B with more than 1000-fold selectivity over monoamine oxidase A (MAO-A) ($IC_{50} > 10000$ nM) with IC_{50} values of 5.72 nM and 58 nM, respectively. In a serotonergic mouse model study, CC112273 concentrations up to 84 nM (approximately 4-fold higher than the mean steady-state C_{max} of CC112273 [19.4 nM] in RMS patients receiving ozanimod 920 microgram QD for 12 weeks) did not induce signs of serotonin syndrome in normal mice or exacerbate mild serotonin syndrome in mice induced by 5-hydroxytryptophan. In a clinical study with ZEPOSIA, CC112273 and CC1084037 had no inhibition effect on human platelet MAO-B activity. In active-controlled MS clinical trials, the use of serotonergic agents including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) was not excluded and no patients with serotonin syndrome were identified.

CYP Enzymes

Ozanimod, CC112273, CC1084037 and other metabolites have no inhibitory effect on CYPs 1A2, 2B6, 2C19, 2C8, 2C9, 2D6, and 3A and no induction effect on CYPs 1A2, 2B6, and 3A.

Drug Transporters

Ozanimod, CC112273, CC1084037 and other metabolites have no inhibitory effect on P-glycoprotein, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, and MATE2-K. CC112273 and CC1084037 inhibit BCRP with IC_{50} values of 25.2 nM and 22.8 nM, respectively. At clinically relevant concentrations of CC112273 and CC1084037, inhibition of BCRP is not expected.

4.6. FERTILITY, PREGNANCY AND LACTATION

4.6.1. Effects on fertility

No fertility data are available in humans. No effects on fertility were observed in animal studies. Ozanimod had no effect on fertility in rats up to 30 mg/kg/day (estimated systemic exposure more than 2000 times the anticipated clinical exposure) in a study in which both male and female animals were treated orally and mated. There was no apparent effect on sperm count/motility. Data from animals does not suggest that ozanimod would be associated with an increased risk of reduced fertility.

4.6.2. Use in pregnancy (Category D)

There are no adequate data on the developmental risk associated with the use of ZEPOSIA in pregnant women. If the patient becomes pregnant or plans to become pregnant while taking ZEPOSIA, she should be informed of the potential hazards and discontinuation of therapy should be considered.

Ozanimod and/or its metabolites crossed the placental barrier in pregnant rats and rabbits. When administered during organogenesis, ozanimod was teratogenic in the rat at oral doses of 5 mg/kg/day or higher (426 times the clinical exposure on an AUC basis) with a no effect dose of 1 mg/kg/day (63.7 times the clinical exposure). The most common findings were anasarca, malpositioned testes and delayed/incomplete ossification. Rabbits showed an increase in malformation of great blood vessels,

incomplete ossification and malpositioned vertebrae at oral doses of 0.6 mg/kg/day or higher (8 times the clinical exposure on an AUC basis) with a no effect dose of 0.2 mg/kg/day (2.4 times the clinical exposure).

The vascular effects, as well as an increased incidence of post-implantation loss and resorptions seen in rats (5 mg/kg/day, 426 times the clinical exposure) and rabbits (2 mg/kg/day; 27.6 times the clinical exposure) are consistent with the pharmacological mechanism of ozanimod, since the sphingosine-1-phosphate receptor is involved in vascular formation during embryogenesis.

Women of childbearing potential should use effective contraception during ZEPOSIA treatment and for 3 months after stopping ZEPOSIA.

4.6.3. Use in lactation

There are no data on the presence of ozanimod in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Ozanimod and its metabolites are present in rat milk. Reduced immunocompetence was evident in juvenile rats following oral administration.

Due to the potential for serious adverse reactions to ozanimod/metabolites in nursing infants, women receiving ozanimod should not breastfeed.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive and the use of machines have been performed.

4.8. ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

4.8.1. Tabulated Summary of Adverse Events

Multiple Sclerosis

The Safety Population for the two active-controlled Phase 3 MS clinical trials included 2659 subjects, of whom 882 subjects received at least 1 dose of ozanimod 920 microgram, 892 subjects received at least 1 dose of ozanimod 460 microgram, and 885 subjects received at least 1 dose of IFN beta-1a.

The system organ classes with the highest proportions of subjects reporting AEs were Infections and Infestations, Nervous System Disorders, and Investigations. Adverse events reported by $\geq 2\%$ of subjects in any treatment group are provided in Table 2.

Table 2: Treatment-emergent Adverse Events Reported in $\geq 2\%$ of Subjects in Any Treatment Group — MS (Safety Population)

Preferred Term	IFN beta-1a 30 microgram N = 885 n (%)	ZEPOSIA 460 microgram N = 892 n (%)	ZEPOSIA 920 microgram N = 882 n (%)
Nasopharyngitis	84 (9.5)	103 (11.5)	98 (11.1)
Headache	78 (8.8)	82 (9.2)	78 (8.8)
Upper respiratory tract infection	61 (6.9)	67 (7.5)	52 (5.9)
Alanine aminotransferase increased	28 (3.2)	41 (4.6)	47 (5.3)
Influenza like illness	442 (49.9)	44 (4.9)	44 (5.0)
Orthostatic hypotension	28 (3.2)	32 (3.6)	38 (4.3)
Back pain	23 (2.6)	31 (3.5)	35 (4.0)

Preferred Term	IFN beta-1a 30 microgram N = 885 n (%)	ZEPOSIA 460 microgram N = 892 n (%)	ZEPOSIA 920 microgram N = 882 n (%)
Hypertension	18 (2.0)	31 (3.5)	30 (3.4)
Urinary tract infection	27 (3.1)	30 (3.4)	36 (4.1)
Pharyngitis	20 (2.3)	30 (3.4)	28 (3.2)
Gamma-glutamyltransferase	11 (1.2)	26 (2.9)	40 (4.5)
Arthralgia	14 (1.6)	23 (2.6)	20 (2.3)
Depression	25 (2.8)	22 (2.5)	23 (2.6)
Insomnia	20 (2.3)	22 (2.5)	21 (2.4)
Fatigue	16 (1.8)	21 (2.4)	20 (2.3)
Rhinitis	13 (1.5)	20 (2.2)	19 (2.2)
Bronchitis	17 (1.9)	18 (2.0)	23 (2.6)
Pain in extremity	18 (2.0)	18 (2.0)	15 (1.7)
Diarrhoea	12 (1.4)	18 (2.0)	12 (1.4)
Abdominal pain upper	9 (1.0)	17 (1.9)	20 (2.3)
Pyrexia	56 (6.3)	17 (1.9)	16 (1.8)
Respiratory tract infection viral	11 (1.2)	15 (1.7)	21 (2.4)
Sinusitis	19 (2.1)	15 (1.7)	13 (1.5)
Respiratory tract infection	21 (2.4)	13 (1.5)	18 (2.0)
Anaemia	19 (2.1)	13 (1.5)	9 (1.0)

IFN = interferon.

Note: Preferred terms are listed in order of decreasing frequency in the ozanimod 920 microgram treatment group.

Ulcerative Colitis

The safety of ZEPOSIA was evaluated in two randomised, double-blind, placebo-controlled clinical trials, UC Study 1 (TRUENORTH-I, n=429) and in UC Study 2 (TRUENORTH-M, n =230), in adult subjects with moderately to severely active ulcerative colitis (*see Section 5.1 - Clinical Trials*). Additional data from the induction period of a Phase 2, UC Study 3 (TOUCHSTONE) randomised, double-blind, placebo-controlled trial included 67 patients who received ZEPOSIA 920 microgram. The system organ classes with the highest proportions of subjects reporting AEs were Infections and Infestations and Gastrointestinal Disorders. Adverse events reported by $\geq 2\%$ of subjects in any treatment group during the induction (UC Study 1 and 3) and maintenance period (UC Study 2) are provided in Table 3 and Table 4, respectively.

Table 3: Treatment-emergent Adverse Events Reported in $\geq 2\%$ of Subjects in Any Treatment Group — Induction Period (UC Study 1 and 3 Safety Population)

Preferred Term	Placebo N = 281 n (%)	ZEPOSIA 920 microgram N = 496 n (%)
Anaemia	16 (5.7)	18 (3.6)
Headache	7 (2.5)	15 (3.0)
Nasopharyngitis	3 (1.1)	15 (3.0)
Nausea	5 (1.8)	14 (2.8)
Pyrexia	3 (1.1)	14 (2.8)
Arthralgia	3 (1.1)	12 (2.4)
Alanine aminotransferase increased	0 (0)	12 (2.4)
Ulcerative colitis	8 (2.8)	8 (1.6)

Table 4: Treatment-emergent Adverse Events Reported in $\geq 2\%$ of Subjects in Any Treatment Group — Maintenance Period (UC Study 2 Safety Population)

Preferred Term	Placebo N = 227 n (%)	ZEPOSIA 920 microgram N = 230 n (%)
Alanine aminotransferase increased	1 (0.4)	11 (4.8)
Headache	1 (0.4)	8 (3.5)
Arthralgia	6 (2.6)	7 (3.0)
Nasopharyngitis	4 (1.8)	7 (3.0)
Gamma-glutamyltransferase increased	1 (0.4)	7 (3.0)
Oedema peripheral	0 (0)	6 (2.6)
Herpes zoster	1 (0.4)	5 (2.2)
Ulcerative colitis	10 (4.4)	1 (0.4)

4.8.2. Tabulated summary of adverse drug reactions

The adverse drug reactions were determined based on data from the ozanimod clinical development programme. The frequencies of adverse drug reactions are those reported in the ozanimod arms of the two active-controlled MS clinical trials and three placebo-controlled UC clinical trials. In MS trials, 1774 patients received ZEPOSIA with an overall exposure of 2641 person-years. In UC Study 1 and 3, 496 patients had 97.5 person-years of exposure to ZEPOSIA during the induction period. In UC Study 2, 230 patients had 165.5 person-years of exposure to ZEPOSIA during the maintenance period.

The most commonly reported adverse reaction in these MS and UC clinical trials were nasopharyngitis, alanine aminotransferase increased, and gamma-glutamyl transferase increased. The most common adverse reactions leading to discontinuation were related to liver enzyme elevations in the MS clinical trials. The overall safety profile was similar with MS and UC.

The adverse reactions observed in patients treated with ozanimod are listed below by system organ class (SOC) and frequency for all adverse reactions. Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); Uncommon ($\geq 1/1000$ to $< 1/100$).

Table 5: Summary of Adverse Drug Reactions reported in the two MS studies

Frequency	All ADRs
Infections and infestations	
Very Common	Nasopharyngitis
Common	Pharyngitis, Respiratory tract infection viral, Urinary tract infection*
Uncommon	Herpes zoster
Blood and lymphatic system disorders	
Very Common	Lymphopenia
Immune system disorders	
Uncommon	Hypersensitivity (including rash and urticaria*)
Eye disorders	
Uncommon	Macular oedema**
Cardiac disorders	
Common	Bradycardia*^
Vascular disorders	
Common	Hypertension*, Orthostatic hypotension
Investigations	
Common	Alanine aminotransferase increased, Gamma-glutamyltransferase increased, Blood bilirubin increased, Pulmonary function test abnormal***

*At least one of these adverse reactions was reported as serious

** for patients with pre-existing factors (*see Section 4.4*)

***including pulmonary function test decreased, spirometry abnormal, forced vital capacity decreased, carbon monoxide diffusing capacity decreased, forced expiratory volume decreased

^overall incidence; for incidences separated by that reported on Day 1 and after Day 1, see Section 4.8.3 Bradycardia - reduction in heart rate

Table 6: Summary of Adverse Drug Reactions reported in UC Studies

Frequency	All ADRs
Infections and infestations	
Common	Nasopharyngitis, Herpes zoster, Oral herpes
Blood and lymphatic system disorders	
Common	Lymphopenia
Vascular disorders	
Common	Hypertension

Frequency	All ADRs
Investigations	
Common	Alanine aminotransferase increased, Gamma-glutamyltransferase increased
General disorders	
Common	Oedema peripheral
Nervous system disorders	
Common	Headache

4.8.3. Description of Selected Adverse Reactions

Bradycardia – reduction in heart rate

After the initial dose of ZEPOSIA 230 microgram, the greatest mean reduction from baseline in heart rate was 1.2 beats per minute (bpm) in active-controlled MS clinical trials and 0.7 bpm in controlled UC induction clinical trials at Hour 5 on Day 1 returning to near baseline at Hour 6.

In active-controlled MS clinical trials, bradycardia was reported in 0.5% on ZEPOSIA versus 0% on IFN beta-1a on the day of treatment initiation. After Day 1, the incidence of bradycardia was 0.8% on ZEPOSIA versus 0.7% on IFN beta-1a. Patients who experienced bradycardia were generally asymptomatic.

In MS clinical trials, first-degree atrioventricular block was reported in 0.6% (5/882) of patients treated with ZEPOSIA versus 0.2% (2/885) treated with IFN beta-1a IM. Of the cases reported with ZEPOSIA, 0.2% were reported on Day 1 and 0.3% were reported after Day 1.

In UC induction clinical trials, bradycardia was reported on the day of treatment initiation in 1 patient (0.2%) treated with ZEPOSIA compared to none in patients who received placebo. After Day 1, bradycardia was reported in 1 patient (0.2%) treated with ZEPOSIA. In UC Study 2, bradycardia was not reported.

In controlled MS and UC clinical trials with dose escalation, second-or third-degree atrioventricular blocks were not reported with ZEPOSIA.

Increased Blood Pressure

In active-controlled MS clinical trials, patients treated with ZEPOSIA had an average increase of approximately 1 to 2 mm Hg in systolic pressure over IFN beta-1a, and no effect on diastolic pressure. The increase in systolic pressure was first detected after approximately 3 months of treatment initiation and remained stable throughout treatment. Hypertension-related events (hypertension, essential hypertension, and blood pressure increased) were reported as an adverse reaction in 4.5% of patients treated with ZEPOSIA 920 microgram and in 2.3% of patients treated with IFN beta-1a IM.

The mean increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in UC patients treated with ZEPOSIA is similar to patients with MS.

In UC induction clinical trials, the average increase from baseline in SBP was 3.7 mm Hg in patients treated with ZEPOSIA and 2.3 mm Hg in patients treated with placebo. In UC Study 2, the average increase from baseline in SBP was 5.1 mm Hg in patients treated with ZEPOSIA and 1.5 mm Hg in patients treated with placebo. There was no effect on DBP.

Hypertension events were reported in 1.2% of patients treated with ZEPOSIA 920 microgram and none in patients treated with placebo in UC induction clinical trials, and in 2.2% and 2.2% of patients in UC Study 2, respectively. Hypertensive crisis was reported in one patient receiving ZEPOSIA and one patient receiving placebo.

Elevated Hepatic Enzymes

In active-controlled MS clinical trials, elevations of ALT to 5-fold the upper limit of normal (ULN) or greater occurred in 1.6% of patients treated with ZEPOSIA 920 microgram and 1.3% of patients on interferon (IFN) beta-1a. Elevations of 3-fold the ULN or greater occurred in 5.5% of patients on ZEPOSIA and 3.1% of patients on IFN beta-1a. The median time to elevation 3-fold the ULN was 6 months. The majority (79%) continued treatment with ZEPOSIA with values returning to < 3 times the ULN within approximately 2-4 weeks.

In clinical trials, ZEPOSIA was discontinued for a confirmed elevation greater than 5-fold the ULN. Overall, the discontinuation rate due to elevations in hepatic enzymes was 1.1% of patients on ZEPOSIA 920 microgram and 0.8% of patients on IFN beta-1a.

In UC Study 1, elevations of ALT to 5-fold the ULN or greater occurred in 0.9% of patients treated with ZEPOSIA 920 microgram and 0.5% of patients who received placebo, and in UC Study 2, elevations occurred in 0.9% of patients and no patients, respectively. In UC Study 1, elevations of ALT to 3-fold the ULN or greater occurred in 2.6% of UC patients treated with ZEPOSIA 920 microgram and 0.5% of patients who received placebo. In UC Study 2 elevations occurred in 2.3% of patients receiving ZEPOSIA and no patients on placebo.

In controlled and uncontrolled UC trials, the majority of patients with ALT greater than 3 fold the ULN continued treatment with ZEPOSIA with values returning to less than 3 fold the ULN within approximately 2 to 4 weeks.

In clinical trials, ZEPOSIA was discontinued for a confirmed elevation of ALT or AST greater than 5-fold the ULN. Overall, the discontinuation rate due to elevations in hepatic enzymes was 1.1% of MS patients on ZEPOSIA 920 microgram and 0.8% of patients on IFN beta-1a. Overall, the discontinuation rate because of elevations in hepatic enzymes was 0.4% in patients treated with ZEPOSIA 920 microgram, and none in patients who received placebo in the controlled UC trials.

Blood Lymphocyte Count Reduction

The proportion of patients who experienced lymphocyte counts less than $0.2 \times 10^9/L$ was 3.3% in MS Study 1 and 2 and less than or equal to 3% in UC controlled trials. These values generally returned to greater than $0.2 \times 10^9/L$ while patients remained on treatment with ZEPOSIA. In the MS and UC clinical trials, after discontinuing ZEPOSIA 920 microgram, the median time to recovery of peripheral blood lymphocytes to the normal range was 30 days, with approximately 80% to 90% of patients recovering within 3 months.

Infections

In active-controlled MS clinical trials, the overall rate of infections (35%) with ZEPOSIA 920 microgram was similar to IFN beta-1a IM. ZEPOSIA increased the risk of upper respiratory tract infections and urinary tract infection. The overall rate of serious infections was similar between ZEPOSIA (1%) and IFN beta-1a IM (0.8%) in MS clinical trials.

In UC induction clinical trials, the overall rate of infections and rate of serious infections in patients treated with ZEPOSIA were similar to that in patients who received placebo (9.9% vs. 10.7% and 0.8% vs. 0.4%, respectively). In UC Study 2, the overall rate of infections in patients treated with ZEPOSIA was higher than in patients treated with placebo (23% vs. 12%) and the rate of serious infections was similar (0.9% vs. 1.8%).

Progressive Multifocal Leukoencephalopathy was reported with ZEPOSIA.

Herpetic Infections

Cases of localised herpes virus infection (e.g., herpes zoster and herpes simplex) were seen in clinical trials of ZEPOSIA.

In active-controlled MS trials, herpes zoster was reported as an adverse reaction in 0.6% of patients treated with ZEPOSIA 920 microgram and in 0.2% of patients on IFN beta-1a.

In UC induction clinical trials, herpes zoster was reported in 0.4% of patients who received ZEPOSIA and none in patients who received placebo. In UC Study 2, herpes zoster was reported in 2.2% of patients who received ZEPOSIA and 0.4% of patients who received placebo. None were serious or disseminated.

Macular Oedema

In the active-controlled MS clinical trials, macular oedema was observed in 1 (0.1%) patient with ZEPOSIA 920 microgram, 3 (0.3%) patients with ZEPOSIA 460 microgram and none with IFN beta-1a.

Macular oedema was reported in a total of 1 (0.2%) patient in UC induction clinical trials, 1 (0.4%) patient in UC Study 2 treated with ZEPOSIA, and in no patients who received placebo.

Hypersensitivity

Hypersensitivity, including rash and urticaria, has been reported with ZEPOSIA in active-controlled MS clinical trials at a frequency of uncommon.

Respiratory system

Minor dose-dependent reductions in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were observed with ZEPOSIA treatment.

At months 3 and 12 of treatment in MS clinical trials, median changes from baseline in the ZEPOSIA 920 microgram group were as follows: FEV1 -0.07 L and -0.1 L, and FVC -0.05 L and -0.065 L, respectively, with smaller changes from baseline in the IFN beta-1a group (FEV1: -0.01 L and -0.04 L, FVC: 0.00 L and -0.02 L).

Similar to MS clinical trials, in UC induction clinical trials, small mean reductions in pulmonary function tests were observed with ZEPOSIA relative to placebo (FEV1 and FVC). There were no further reductions with longer term treatment with ZEPOSIA in UC Study 2 and these small changes in pulmonary function tests were reversible in patients re-randomised to placebo.

4.8.4. Post-marketing Experience

The following events have been identified during post-marketing use of ozanimod. Because reports are voluntary from a population of unknown size, an estimate of frequency cannot be made.

Hepatobiliary Disorders: liver injury

4.8.5. Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>

4.9. OVERDOSE

In the event of overdose, patients should be managed by symptomatic and supportive care.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

5.1.1. Mechanism of action

Ozanimod is a potent sphingosine 1-phosphate (S1P) receptor modulator, which binds with a high affinity to S1P receptor subtypes 1 and 5. Ozanimod has minimal or no activity on S1P2, S1P3, and S1P4. In vitro, ozanimod and its major active metabolites demonstrated similar activity and selectivity for S1P1 and S1P5. Ozanimod causes the retention of lymphocytes in lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis and ulcerative colitis is unknown but may involve the reduction of lymphocyte migration into the central nervous system and intestine.

5.1.2. Cardiac Electrophysiology

Ozanimod may cause a transient reduction in heart rate on initiation of dosing. A dose escalation schedule of ZEPOSIA 230 microgram followed by doses of 460 microgram, and 920 microgram attenuates the magnitude of heart rate reductions.

In a randomised, positive- and placebo-controlled thorough QT study using a 14-day dose-escalation regimen of 230 microgram QD for 4 days, 460 microgram QD for 3 days, 920 microgram QD for 3 days, and 1.84 mg QD for 4 days in healthy subjects, no evidence of QTc prolongation was observed as demonstrated by the upper boundary of the 95% one-sided confidence interval (CI) that was below 10 ms. Concentration-QTc analysis for ozanimod and the major active metabolites, CC112273 and CC1084037, using data from another Phase 1 study showed the upper boundary of the 95% CI for model derived QTc (corrected for placebo and baseline) below 10 ms at maximum concentrations achieved with ZEPOSIA doses \geq 920 microgram once daily.

5.1.3. Reduction in Blood Lymphocyte Counts

In active-controlled MS and UC clinical trials, mean lymphocyte counts decreased to approximately 45% of baseline at 3 months (approximate mean blood lymphocyte counts $0.8 \times 10^9/L$) and remained stable during treatment with ZEPOSIA.

After discontinuing ZEPOSIA 920 microgram, the median time to recovery of peripheral blood lymphocytes to the normal range was approximately 30 days, with approximately 80% to 90% of patients recovering within 3 months.

5.1.4. Reduction in Faecal Calprotectin

In patients with UC, treatment with ZEPOSIA resulted in a decrease in the inflammatory marker, Faecal Calprotectin (FCP) during UC Study 1, which was maintained throughout UC Study 2.

5.1.5. Clinical trials

Multiple Sclerosis

ZEPOSIA was evaluated in two randomised, double-blind, double-dummy, parallel-group, active controlled clinical trials of similar design and endpoints, in patients with relapsing forms of MS (RMS) treated for at least 1 year (Study 1 – SUNBEAM - Treatment continued for all patients until the last enrolled patient completed 1 year) and 2 years (Study 2 - RADIANCE).

The dose of ZEPOSIA was 920 microgram and 460 microgram given orally once daily, with a starting dose of 230 microgram on Days 1-4, followed by an escalation to 460 microgram on Days 5-7, and followed by the assigned dose on Day 8 and thereafter. The dose of IFN beta-1a, the active comparator, was 30 microgram given intramuscularly once weekly. Both studies included patients who had experienced at least one relapse within the prior year, or one relapse within the prior two years with evidence of at least a gadolinium-enhancing (GdE) lesion in the prior year and had an Expanded Disability Status Scale (EDSS)

score from 0 to 5.0. Neurological evaluations were performed at baseline, every 3 months, and at the time of a suspected relapse. MRIs were performed at baseline (Studies 1 and 2), 6 months (Study 1), 1 year (Studies 1 and 2), and 2 years (Study 2).

The primary outcome of both Study 1 and Study 2 was the annualised relapse rate (ARR) over 12 months for Study 1 and 24 months for Study 2. The key secondary outcome measures included: 1) the number of new or enlarging MRI T2 hyperintense lesions over 12 and 24 months 2) the number of MRI T1 GdE lesions at 12 and 24 months, and 3) the time to confirmed disability progression, defined as at least a 1-point increase from baseline EDSS sustained for 12 weeks. Confirmed disability progression was prospectively evaluated in a pooled analysis of Studies 1 and 2. An additional MRI outcome measure was the mean percentage change from baseline in normalised brain volume.

In Study 1, 1346 patients were randomised to receive ZEPOSIA 920 microgram (n = 447), ZEPOSIA 460 microgram (n= 451), or IFN beta-1a (n = 448); 94% of ZEPOSIA-treated 920 microgram, 94% of ZEPOSIA- treated 460 microgram, and 92% of IFN beta-1a-treated patients completed the study. Mean (median) age was 35.6 (35) years, 66% were female, mean (median) time since MS symptom onset was 7 (5.2) years. The mean (median) EDSS score at baseline was 2.62 (2.5); 70% had not been treated with a disease-modifying therapy. At baseline, the mean number of relapses in the prior year was 1.3 and 47% of patients had one or more T1 Gd-enhancing lesions (mean 1.7).

The median duration of treatment was 13.6 months.

In Study 2, 1313 patients were randomised to receive ZEPOSIA 920 microgram (n = 433), ZEPOSIA 460 microgram (n = 439), or IFN beta-1a (n = 441); 90% of ZEPOSIA-treated 920 microgram, 85% of ZEPOSIA- treated 460 microgram, and 85% of IFN beta-1a-treated patients completed the study. Mean (median) age was 35.5 (35) years, 67% were female, mean (median) time since MS symptom onset was 6.5 (4.8) years, and mean (median) EDSS score at baseline was 2.51 (2.5); 71% had not been treated with a disease-modifying therapy. At baseline, the mean number of relapses in the prior year was 1.3 and 43% of patients had one or more T1 Gd-enhancing lesions (mean 1.7). The median duration of treatment was 24 months.

The ARR was significantly lower in patients treated with ozanimod 920 microgram than in patients who received IFN beta-1a 30 microgram IM. The number of new or enlarging T2 lesions and the number of GdE lesions was significantly lower in patients treated with ZEPOSIA than in patients who received IFN beta-1a. Three month confirmed disability progression was low and similar between ZEPOSIA and IFN beta-1a-treated patients over 2 years. The difference was not statistically significant.

A consistent reduction of the ARR compared to IFN beta-1a was observed in subgroups defined by sex, age, prior DMT therapy, and baseline disease activity.

Table 7: Key Clinical and MRI Endpoints in RMS Patients from Study 1 and Study 2

Endpoints	Study 1 (≥ 1 year)		Study 2 (2 year)	
	ZEPOSIA 920 microgram (n=447) %	IFN beta-1a 30 microgram (n=448) %	ZEPOSIA 920 microgram (n=433) %	IFN beta-1a 30 microgram (n=441) %
Clinical Endpoints				
Annualised Relapse Rate (Primary Endpoint) Relative Reduction	0.181	0.350	0.172	0.276
	48% (p<0.0001)		38% (p<0.0001)	
Proportion Relapse-free	78% (p=0.0002) ¹	66%	76% (p=0.0012) ¹	64%

Endpoints	Study 1 (≥ 1 year)		Study 2 (2 year)	
	ZEPOSIA 920 microgram (n=447) %	IFN beta-1a 30 microgram (n=448) %	ZEPOSIA 920 microgram (n=433) %	IFN beta-1a 30 microgram (n=441) %
Proportion of Patients with 3-Month Confirmed Disability Progression ² Hazard Ratio	7.6% ZEPOSIA vs. 7.8% IFN beta-1a 0.95 (p=0.7651)			
Proportion of Patients with 6-Month Confirmed Disability Progression ² Hazard Ratio	5.8% ZEPOSIA vs. 4.0% IFN beta-1a 1.413 (p=0.1126)			
MRI Endpoints				
Mean number of new or enlarging T2 hyperintense lesions per MRI ³ Relative Reduction	1.465	2.836	1.835	3.183
	48% (p<0.0001)		42% (p<0.0001)	
Mean number of T1 Gd-enhancing lesions ⁴ Relative Reduction	0.160	0.433	0.176	0.373
	63% (p<0.0001)		53% (p=0.0006)	

¹ Log-rank test; ² Prospectively planned pooled analysis of Studies 1 and 2; ³ Through the treatment period;

⁴ At the end of the treatment period for each study.

In Studies 1 and 2, treatment with ZEPOSIA 920 microgram resulted in reductions in mean percent change from baseline in normalised brain volume compared to IFN beta-1a (-0.41% versus -0.61%, and -0.71% versus -0.94%, respectively, nominal p-value <0.0001 for both studies).

Long-term Data

Patients who completed the Phase 3 Studies 1 and 2 could enter an open label extension study (Study 3 - DAYBREAK). Of the 751 patients initially randomised to ozanimod 920 microgram and treated for up to 3 years, the (adjusted) ARR between year 2 and 3 of treatment was 0.124.

Ulcerative Colitis

The efficacy and safety of ZEPOSIA were evaluated in two multi-centre, randomised, double-blind, placebo-controlled clinical trials [UC Study 1 (TRUENORTH-I) and UC Study 2 (TRUENORTH-M)] in adult patients with moderately to severely active ulcerative colitis. UC Study 1 included patients who were randomised 2:1 to ozanimod 920 microgram or placebo. The total population included an additional group who received ZEPOSIA 920 microgram open-label. The 10-week induction period was followed by a 42-week, randomised, withdrawal maintenance period (UC Study 2) for a total of 52 weeks of therapy. Patients could have had an inadequate response, loss of response, or intolerance to a biologic (e.g., TNF blocker and/or vedolizumab), corticosteroids, and/or immunomodulators (e.g. 6-mercaptopurine and azathioprine). Patients were to be receiving treatment with oral aminosalicylates and/or corticosteroids.

Disease assessment was based on the Mayo score, which ranges from 0 to 12 and has four subscores from 0 (normal) to 3 (most severe): stool frequency, rectal bleeding, findings on centrally-reviewed endoscopy, and physician global assessment. Moderately to severely active ulcerative colitis was defined at baseline (Week

0) as a Mayo score of 6 to 12, including a Mayo endoscopy subscore ≥ 2 . An endoscopy score of 2 was defined by marked erythema, lack of vascular pattern, friability, erosions; and a score of 3 was defined by spontaneous bleeding, ulceration.

UC Study 1 (TRUENORTH-I)

In the UC Study 1 (TRUENORTH-I), patients were randomised to either ZEPOSIA 920 microgram given orally once daily (n=429) or placebo (n=216) beginning with a dose titration (*see Section 4.2*). There were another 361 patients who received open-label ZEPOSIA 920 microgram orally once daily. Patients received concomitant aminosalicylates (e.g., mesalazine 71%; sulfasalazine 13% of the total population) and/or oral corticosteroids (33% of randomised patients) at a stable dose prior to and during the induction period.

There were 30% of patients who had an inadequate response, loss of response or intolerant to TNF blockers. Of these patients, 63% received at least two or more biologics including TNF blockers; 47% received an integrin receptor blocker (e.g. vedolizumab); 36% failed to ever respond to at least one TNF blocker; 65% lost response to a TNF blocker. There were 41% of patients who failed and/or were intolerant to immunomodulators. At baseline, patients had a median Mayo score of 9, with 65% of patients less than or equal to 9 and 35% having greater than 9.

The primary endpoint was clinical remission at Week 10, defined as a Three-component Mayo: Rectal bleeding subscore = 0 and Stool frequency subscore ≤ 1 (and a decrease of ≥ 1 point from the Baseline Stool Frequency subscore) and Endoscopy subscore ≤ 1 without friability.

Key secondary endpoints at Week 10 were clinical response, endoscopic improvement, and mucosal healing. Clinical response with a definition of Three-component Mayo (a reduction from Baseline in the 9-point Mayo score of ≥ 2 points and $\geq 35\%$, and a reduction from Baseline in the Rectal Bleeding subscore of ≥ 1 point or an absolute Rectal Bleeding subscore of ≤ 1 point), endoscopic improvement with a definition of Endoscopy subscore of ≤ 1 point, and mucosal healing defined as Endoscopy subscore of ≤ 1 point and a Geboes index score < 2.0 .

A significantly greater proportion of patients treated with ozanimod achieved clinical remission, clinical response, endoscopic improvement, and mucosal healing compared to placebo at Week 10 as shown in Table 8.

Table 8: Proportion of patients meeting efficacy endpoints in the induction period from UC Study 1 - TRUENORTH-I (at Week 10)

	ZEPOSIA 920 microgram N=429 ^f		Placebo N=216 ^f		Treatment Difference % ^a (95% CI)
	n	%	n	%	
Clinical remission^b	79	18%	13	6%	12% (7.5, 17.2)^f
Without prior TNF blocker exposure	66/299	22%	10/151	7%	
Prior TNF blocker exposure	13/130	10%	3/65	5%	
Clinical response^c	205	48%	56	26%	22% (14.4, 29.3)^f
Without prior TNF blocker exposure	157/299	53%	44/151	29%	
Prior TNF blocker exposure	48/130	37%	12/65	19%	
Endoscopic improvement^d	117	27%	25	12%	16% (9.7, 21.7)^f

	ZEPOSIA 920 microgram N=429^f		Placebo N=216^f		Treatment Difference %^a (95% CI)
	n	%	n	%	
Without prior TNF blocker exposure	97/299	32%	18/151	12%	
Prior TNF blocker exposure	20/130	15%	7/65	11%	
Mucosal healing^e	54	13%	8	4%	9% (4.9, 12.9)^g
Without prior TNF blocker exposure	47/299	16%	6/151	4%	
Prior TNF blocker exposure	7/130	5%	2/65	3%	

CI = confidence interval; TNF = tumor necrosis factor.

^a Treatment difference (adjusted for stratification factors of prior TNF blocker exposure and corticosteroid use at baseline).

^b Clinical remission is defined as: RBS = 0, SFS ≤ 1 (and a decrease of ≥ 1 point from the baseline SFS), and endoscopy subscore ≤ 1 without friability.

^c Clinical response is defined as a reduction from baseline in the 9-point Mayo score of ≥ 2 and ≥ 35%, and a reduction from baseline in the RBS of ≥ 1 or an absolute RBS of ≤ 1.

^d Endoscopic improvement is defined as a Mayo endoscopic score ≤ 1 without friability.

^e Endoscopic improvement with histologic remission defined as both Mayo endoscopic score ≤ 1 without friability and histological remission (defined as no neutrophils in the epithelial crypts or lamina propria and no increase in eosinophils, no crypt destruction, and no erosions, ulcerations, or granulation Geboes index score < 2.0).

^f p=<0.0001

^g p=<0.001

UC Study 2 (TRUENORTH-M)

In order to be randomised to treatment in UC Study 2 (TRUENORTH-M), patients had to have received ZEPOSIA 920 microgram and have a clinical response at Week 10 of UC Study 1. Patients could have come from either UC Study 1 (TRUENORTH-I) or from a group who received ZEPOSIA 920 microgram open-label. Patients were re-randomised in a double-blinded fashion (1:1) to receive either ZEPOSIA 920 microgram (n=230) or placebo (n=227) for 42 weeks. The total study duration was 52 weeks, including both studies. Efficacy assessments were at Week 52. Concomitant aminosalicylates were required to remain stable through Week 52. Patients on concomitant corticosteroids were to taper their dose upon entering the maintenance study.

At study entry, 35% of patients were in clinical remission, 29% of patients were on corticosteroids and 31% of patients were previously treated with TNF blockers.

The primary endpoint was the proportion of patients in clinical remission at Week 52. Key secondary endpoints at Week 52 were the proportion of patients with clinical response, endoscopic improvement, endoscopic improvement with histologic remission, corticosteroid-free clinical remission, mucosal healing and maintenance of clinical remission at Week 52 in the subset of patients in remission at Week 10.

The results of the efficacy endpoints in UC Study 2 are shown in Table 9.

Table 9: Proportion of patients meeting efficacy endpoints in UC Study 2 - TRUENORTH-M (at Week 52)

	ZEPOSIA 920 microgram^a N=230		Placebo^a N=227		Treatment Difference %^a (95% CI)
	n	%	n	%	
Clinical remission^b	85	37%	42	19%	19% (10.8, 26.4)ⁱ
Without prior TNF blocker exposure	63/154	41%	35/158	22%	
Prior TNF blocker exposure	22/76	29%	7/69	10%	
Clinical response^c	138	60%	93	41%	19% (10.4, 28.0)ⁱ
Without prior TNF blocker exposure	96/154	62%	76/158	48%	
Prior TNF blocker exposure	42/76	55%	17/69	25%	
Endoscopic improvement^d	105	46%	60	26%	19% (11.0, 27.7)ⁱ
Without prior TNF blocker exposure	77/154	50%	48/158	30%	
Prior TNF blocker exposure	28/76	37%	12/69	17%	
Maintenance of clinical remission at Week 52 in the subset of patients in remission at Week 10^e	41/79	52%	22/75	29%	24% (9.1, 38.6)^k
Without prior TNF blocker exposure	37/64	58%	19/58	33%	
Prior TNF blocker exposure	4/15	27%	3/17	18%	
Corticosteroid-free clinical remission^f	73	32%	38	17%	15% (7.8, 22.6)^j
Without prior TNF blocker exposure	55/154	36%	31/158	20%	
Prior TNF blocker exposure	18/76	24%	7/69	10%	
Mucosal healing^g	68	30%	32	14%	16% (8.2, 22.9)^j
Without prior TNF blocker exposure	51/154	33%	28/158	18%	
Prior TNF blocker exposure	17/76	22%	4/69	6%	
Durable clinical remission^h	41	18%	22	10%	8% (2.8, 13.6)^l
Without prior TNF blocker exposure	37/154	24%	19/158	12%	

	ZEPOSIA		Placebo^a		Treatment Difference %^a (95% CI)
	920 microgram^a		N=227		
	N=230		n	%	
	n	%	n	%	
Prior TNF blocker exposure	4/76	5%	3/69	4%	

CI = confidence interval; TNF = tumor necrosis factor.

^a Treatment difference (adjusted for stratification factors of clinical remission and concomitant corticosteroid use at Week 10).

^b Clinical remission is defined as: RBS = 0 point and SFS ≤ 1 point (and a decrease of ≥ 1 point from the baseline SFS) and endoscopy subscore ≤ 1 point without friability.

^c Clinical response is defined as: A reduction from baseline in the 9-point Mayo score of ≥ 2 points and ≥ 35%, and a reduction from baseline in the RBS of ≥ 1 point or an absolute RBS of ≤ 1 point.

^d Endoscopic improvement is defined as: Endoscopy subscore of ≤ 1 point without friability.

^e Maintenance of remission defined as clinical remission at Week 52 in the subset of patients in clinical remission at Week 10.

^f Corticosteroid-free remission is defined as clinical remission at Week 52 while off corticosteroids for ≥ 12 weeks.

^g Mucosal healing is defined as both Mayo endoscopic score ≤ 1 without friability and histological remission (defined as no neutrophils in the epithelial crypts or lamina propria and no increase in eosinophils, no crypt destruction, and no erosions, ulcerations, or granulation Geboes index score < 2.0)

^h Durable clinical remission is defined as clinical remission at Week 10 and at Week 52 in all subjects who entered the maintenance period.

ⁱ p=<0.0001

^j p=<0.001

^k p=0.0025

^l p=0.0030

Long-term data

Patients who did not achieve clinical response at the end of UC Study 1, lost response in UC Study 2 or completed the UC studies were eligible to enter an open label extension study (OLE) and received ZEPOSIA 920 microgram. A total of 821 of the 1012 eligible patients entered the OLE. In this open-label extension study, patients were observed for up to 142 weeks.

Additional clinical data

UC Study 3 (TOUCHSTONE), a 33 week placebo controlled Phase 2 study in patients with moderate to severe ulcerative colitis demonstrated a significant treatment difference for ZEPOSIA 920 microgram (n=67) relative to placebo (n=65) in clinical remission (using the pre-specified 4-component Total Mayo Score) of 16% (p=0.0482) at Week 9 and 21% (p=0.0108) at Week 33.

5.2. PHARMACOKINETIC PROPERTIES

Ozanimod is extensively metabolised in humans to form a number of circulating active metabolites, including two major active metabolites, CC112273 and CC1084037, with similar activity and selectivity for S1P1 and S1P5 to the parent drug. Approximately 94% of circulating total active drug exposure is represented by ozanimod (6%), CC112273 (73%), and CC1084037 (15%) in humans. The maximum plasma concentration (C_{max}) and area under the curve (AUC) for ozanimod, CC112273, and CC1084037 increased proportionally over the dose range of ZEPOSIA 460 microgram to 920 microgram (0.5 to 1 time the recommended dose). At a dose of 920 microgram orally once daily in RMS, the geometric mean [coefficient of variation (CV%)] C_{max} and AUC_{0-24h} at steady state were 231.6 pg/mL (37.2%) and 4223 pg*h/mL (37.7%), respectively, for ozanimod, and 6378 pg/mL (48.4%) and 132861 pg*h/mL (45.6%), respectively, for CC112273. C_{max} and AU_{C0-24h} for CC1084037 are approximately 20% of that for CC112273. Factors affecting CC112273 are applicable for CC1084037 as they are interconverting metabolites.

Population pharmacokinetic analysis indicated that there were no meaningful differences in these pharmacokinetic parameters in patients with relapsing MS or UC.

5.2.1. Absorption

The T_{max} of ozanimod is approximately 6-8 hours. Administration of ZEPOSIA with a high-fat, high-calorie meal (approximately 900 to 1100 calories with 150, 250 to 360, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) had no effect on ozanimod exposure (C_{max} and AUC). Ozanimod may be taken without regard to meals.

In a study of female rats, absolute oral bioavailability of ozanimod was 64% with an oral capsule formulation.

5.2.2. Distribution

The mean (CV%) apparent volume of distribution of ozanimod (V_z/F) was 5590 L (27%), indicating extensive tissue distribution. Binding of ozanimod to human plasma proteins is approximately 98.2%. Binding of CC112273 and CC1084037 to human plasma proteins is approximately 99.8% and 99.3%, respectively. Ozanimod and its metabolites do not bind extensively to whole blood components, such as red blood cells.

5.2.3. Metabolism

Ozanimod was extensively metabolised in humans with a number of metabolites identified in plasma, urine and faeces. Multiple enzyme systems play an important role in the metabolism of ozanimod and no single enzyme system predominates in the overall metabolism of ozanimod. The oxidative pathway to formation of carboxylate metabolite RP101988 is mediated by ALDH/ADH while formation of RP101075 by dealkylation is predominantly carried out by CYP3A4. RP101075 is N-acetylated by NAT-2 to form RP101442 or deaminated by MAO-B to form the major metabolite CC112273.

CC112273 is either reduced to form CC1084037 or undergoes CYP2C8 mediated oxidation to form RP101509. CC1084037 is oxidised rapidly to form CC112273 by AKR 1C1/1C2, and/or 3 β - and 11 β -HSD and undergoes reversible metabolism to CC112273. The oxido-reduction interconversion between CC112273 and CC1084037 favours CC112273 and there are no direct metabolites of CC1084037 other than its metabolism to CC112273 and subsequent elimination via that pathway. Gut microbial flora plays an important role in vivo, via anaerobic reductive metabolism of the oxadiazole ring system in the formation of many inactive metabolites.

5.2.4. Excretion

Following a single oral 920 microgram dose of [^{14}C]-ozanimod, approximately 26% and 37% of the radioactivity was recovered from urine and faeces, respectively, primarily composed of inactive metabolites. Ozanimod, CC112273, and CC1084037 concentrations in urine were negligible, indicating that renal clearance is not an important excretion pathway for ozanimod, CC112273 and CC1084037.

The mean (CV%) apparent oral clearance for ozanimod was approximately 192 L/h (37%). The mean (CV%) plasma half-life ($t_{1/2}$) of ozanimod was approximately 21 hours (15%). Steady state for ozanimod was achieved within 7 days, with the estimated accumulation ratio following repeated oral administration of 920 microgram once daily of approximately 2.

The model-based mean (CV%) effective half-life ($t_{1/2}$) of CC112273 was approximately 11 days (104%) in RMS patients, with mean (CV%) time to steady state of approximately 45 days (45%) and accumulation ratio of approximately 16 (101%). Plasma levels of CC112273 and its direct, interconverting metabolite CC1084037 declined in parallel in the terminal phase, yielding similar $t_{1/2}$ for both metabolites. Steady state attainment and accumulation ratio for CC1084037 are expected to be similar to CC112273.

5.2.5. Renal impairment

In a dedicated renal impairment trial, following a single oral dose of 230 microgram ZEPOSIA, exposures (AUC_{last}) for ozanimod and CC112273 were approximately 27% higher and 23% lower, respectively, in subjects with end stage renal disease (N=8) compared to subjects with normal renal function (N=8). Based on this trial, renal impairment had no clinically important effects on pharmacokinetics of ozanimod or CC112273.

No dose adjustment is needed in patients with renal impairment.

5.2.6. Hepatic impairment

Two studies were conducted with subjects with chronic liver disease, a single dose study, and an 8-day multiple dose study evaluating the 7-day dose escalation followed by a single 920 microgram on Day 8. In both studies, there was no meaningful impact of mild or moderate chronic hepatic impairment (Child Pugh A or B) on the concentrations of ozanimod or the major metabolite CC112273 after the first dose on Day 1. In the 8-day multiple dose hepatic impairment trial, there was also no meaningful impact on ozanimod or CC112273 concentrations on Day 5 or Day 8 of dosing. After dose escalation in the 8-day multiple dose hepatic impairment trial, administration of 920 microgram ozanimod resulted in increased CC112273 and CC1084037 mean unbound AUC_{0-last} (measured up to 64 days post-dose) in subjects with mild or moderate chronic hepatic impairment of 99.64% to 129.74% relative to healthy control subjects. This study did not reach steady state exposure, and the terminal half-life of CC112273 in mild and moderate hepatic impairment was approximately 28 and 64 days, respectively.

The pharmacokinetics of ozanimod were not evaluated in subjects with severe hepatic impairment.

Patients with mild or moderate chronic hepatic impairment (Child-Pugh class A or B) are recommended to complete the 7-day dose escalation regimen, and then take 920 microgram once every other day. Use in patients with severe hepatic impairment is not recommended (Child-Pugh class C).

5.2.7. Pharmacokinetics in Children

No PK data are available on administration of ZEPOSIA to paediatric or adolescent patients (< 18 years of age).

5.2.8. Pharmacokinetics in Elderly

Population pharmacokinetic analyses showed that steady state exposure (AUC) of CC112273 in patients over 65 years of age was approximately 3% to 4% greater than patients over 45 to 65 years of age and 27% greater than adult patients under 45 years of age. There is not a meaningful difference in the pharmacokinetics in elderly patients.

5.2.9. Pharmacokinetics in Smokers

Population PK results showed that CC112273 steady-state exposure (AUC) was approximately 50% lower in smokers than in non-smokers, although for smokers this reduction in exposure did not result in meaningful differences in ALC reduction or an apparent impact on clinical efficacy.

5.2.10. Gender

While population PK of ozanimod are not affected by gender, CC112273 steady-state exposure (AUC) was lower in males than in females. The effect of gender on CC112273 systemic exposure was not deemed clinically meaningful.

5.2.11. Ethnicity

In a dedicated Japanese PK bridging study, following repeated dosing of 920 microgram, ozanimod exposure (C_{max} and AUC_{tau}) were unchanged and CC112273 exposure (C_{max} and AUC_{tau}) were approximately 28% and 43% higher, respectively, in Japanese subjects (N=10) compared to Caucasian subjects (N=12). These differences were not considered clinically meaningful.

5.3. PRECLINICAL SAFETY DATA

5.3.1. Genotoxicity

Ozanimod and multiple metabolites were evaluated for bacterial mutagenicity. These mutagenicity assays examined ozanimod, CC112273, CC1084037, RP101124, RP101988, RP101075, and RP101442, which were all negative for mutagenicity. In vitro aneugenicity/clastogenicity assessment included ozanimod

(negative in the mouse lymphoma), CC112273 (negative in the human peripheral blood lymphocyte assay), and CC1084037 (positive in the TK6 assay). The positive in vitro TK6 result with CC1084037 was assessed using a two-organ in vivo study (negative bone marrow micronucleus assay and a negative hepatic comet assay at doses up to 1000 mg/kg/day for 3 days in mice). Ozanimod was also negative in the in vivo bone marrow micronucleus assay (at doses up to 800 mg/kg/day for 2 days in rats).

Overall, ozanimod and metabolites did not exhibit any in vitro or in vivo genotoxicity concerns.

5.3.2. Carcinogenicity

Ozanimod was evaluated for carcinogenicity in the 6-month Tg.rasH2 mouse bioassay and the two-year rat bioassay. In the 6-month Tg.rasH2 mouse study, a statistically significant increased incidence of hemangiosarcomas was seen at the mid and high dose (25 mg/kg/day and 80 mg/kg/day) across multiple organs. At the low dose (8 mg/kg/day), the hemangiosarcoma incidence was lower and remained within laboratory background levels.

Hemangiosarcomas in mice have been postulated to be a result of chronic stimulation of endothelial cells through the S1P₁ receptor (also known as the endothelial differentiation gene (EDG) 1 receptor). This receptor is abundant on vascular endothelial cells and is important in endothelial cell migration, differentiation, and survival. In mice, S1P₁ agonism results in sustained production of placental growth factor 2 (PlGF2) and subsequently, persistent vascular endothelial cell mitoses. In contrast, rat and human vascular endothelial cells do not release PlGF2 or only transiently release PlGF2 in response to S1P₁ agonism, and subsequently, sustained stimulation and hemangiosarcoma formation are not observed in these species.

Based upon the evidence that hemangiosarcomas formation by S1P₁ agonism is specific to mice and not relevant to humans, the Tg.rasH2 mouse exposure margin for human risk with the top dose of oral ozanimod at 80 mg/kg/day is 17364x. The metabolite exposure margin is 17.3x for CC112273 and is 15.5x for CC1084037. At the NOAEL dose in mice of 8 mg/kg/day, the exposure margins are 1795x for ozanimod, 1.4x for CC112273, and 1.40x for CC1084037.

In the two-year rat bioassay, no incidence of any tumour type was increased at any ozanimod dose (top dose of 2 mg/kg/day).

In rats, the exposure margin at the highest dose tested (2 mg/kg/day), which was the NOAEL, was 135x for ozanimod, 0.29x for CC112273, and 0.176x for CC1084037.

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Capsule content: Microcrystalline cellulose, silicon dioxide, croscarmellose sodium, and magnesium stearate

Capsule shell:

- 230 microgram capsule contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide and red iron oxide
- 460 microgram capsule contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide and red iron oxide
- 920 microgram capsule contains gelatin, titanium dioxide, yellow iron oxide and red iron oxide

Black ink: TekPrint SW-9008 or TekPrint SW-9049

6.2. INCOMPATIBILITIES

Not applicable.

6.3. SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the ARTG. The expiry date can be found on the packaging.

6.4. SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C. Store in the original package.

6.5. NATURE AND CONTENTS OF CONTAINER

Polyvinyl chloride (PVC) / polychlorotrifluoroethylene (PCTFE) / aluminium foil blisters.

ZEPOSIA Initiation Pack

Pack size of 7 capsules (4 x 230 microgram, 3 x 460 microgram)

ZEPOSIA 920 microgram capsules

Pack size of 28 capsules.

6.6. SPECIAL PRECAUTIONS FOR DISPOSAL

None.

6.7. PHYSICOCHEMICAL PROPERTIES

Molecular formula	$C_{23}H_{24}N_4O_3 \cdot HCl$
Molecular weight	440.92
Chemical name	5-(3-((1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile monohydrochloride
Chemical Abstract Service (CAS) registry number	1618636-37-5
Chemical structure	

7. MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine

8. SPONSOR

Sponsored in Australia by:
Celgene Pty Limited
Level 2, 4 Nexus Court
Mulgrave, VIC 3170
Australia

Telephone: 1800 CELGENE (1800 235 4363)

9. DATE OF FIRST APPROVAL

17 July 2020

10. DATE OF REVISION

3 April 2024

Summary table of changes

Section Changed	Summary of new information
4.4	Update “Elevated Hepatic Enzymes” heading to “Liver Injury” and addition of “liver injury”
4.8	Addition of “liver injury” in Post-marketing experience section
5.1, 6.7	Removal of ATC code

ZEPOSIA® is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.